XARELTO 2.5mg Film-coated tablet (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Xarelto 2.5 mg film-coated tablets.
Qualitative and quantitative composition
Each film-coated tablet contains 2.5 mg rivaroxaban. Excipient with known effect: Each film-coated tablet contains 33.92 mg lactose (as monohydrate), see section 4.4. For the full list of excipients, see ...
Pharmaceutical form
Film-coated tablet (tablet). Light yellow, round biconvex tablets (6 mm diameter, 9 mm radius of curvature) marked with the BAYER-cross on one side and 2.5 and a triangle on the other side.
Therapeutic indications
Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary ...
Posology and method of administration
Posology The recommended dose is 2.5 mg twice daily. ACS Patients taking Xarelto 2.5 mg twice daily should also take a daily dose of 75-100 mg ASA or a daily dose of 75-100 mg ASA in addition to either ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Active clinically significant bleeding. Lesion or condition, if considered to be a significant risk for major ...
Special warnings and precautions for use
In ACS patients, efficacy and safety of Xarelto 2.5 mg have been investigated in combination with the antiplatelet agents ASA alone or ASA plus clopidogrel/ticlopidine. Treatment in combination with other ...
Interaction with other medicinal products and other forms of interaction
CYP3A4 and P-gp inhibitors Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold/2.5 fold increase in mean rivaroxaban AUC and a 1.7 ...
Fertility, pregnancy and lactation
Pregnancy Safety and efficacy of Xarelto have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, ...
Effects on ability to drive and use machines
Xarelto has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients ...
Undesirable effects
Summary of the safety profile The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1). Table 1. Number of patients studied, ...
Overdose
Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma exposure ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors ATC code: B01AF01 Mechanism of action Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. ...
Pharmacokinetic properties
Absorption Rivaroxaban is rapidly absorbed with maximum concentrations (C<sub>max</sub>) appearing 2-4 hours after tablet intake. Oral absorption of rivaroxaban is almost complete and oral bioavailability ...
Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity. ...
List of excipients
Tablet core: Microcrystalline cellulose Croscarmellose sodium Lactose monohydrate Hypromellose 2910 Sodium laurilsulphate Magnesium stearate Film-coat: Macrogol 3350 Hypromellose 2910 Titanium dioxide ...
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
PP/Aluminium foil blisters in cartons of 14, 20, 28, 30, 56, 60, 98, 168 or 196 film-coated tablets or perforated unit dose blisters in cartons of 10 1 or 100 1 or in multipacks containing 100 (10 packs ...
Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Bayer AG, 51368 Leverkusen, Germany
Marketing authorization number(s)
EU/1/08/472/025-035 EU/1/08/472/041 EU/1/08/472/046-047
Date of first authorization / renewal of the authorization
Date of first authorisation: 30 September 2008 Date of latest renewal: 22 May 2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
